These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1600380)

  • 1. Approaches to immunization against respiratory syncytial virus.
    Wertz GW; Sullender WM
    Biotechnology; 1992; 20():151-76. PubMed ID: 1600380
    [No Abstract]   [Full Text] [Related]  

  • 2. [The status of research to develop new vaccines against infection caused by the respiratory syncytial virus].
    Pervikov IuV; Litvinov SK
    Vopr Virusol; 1988; 33(5):523-9. PubMed ID: 3064426
    [No Abstract]   [Full Text] [Related]  

  • 3. The immunobiology of respiratory syncytial virus: prospects for a vaccine.
    Norrby E; Akerlind B; Mufson MA
    Adv Exp Med Biol; 1989; 257():147-53. PubMed ID: 2694814
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice.
    Vaux-Peretz F; Chapsal JM; Meignier B
    Vaccine; 1992; 10(2):113-8. PubMed ID: 1539464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein.
    Trudel M; Nadon F; Séguin C; Binz H
    Virology; 1991 Dec; 185(2):749-57. PubMed ID: 1720589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vaccination against respiratory syncytial infection].
    Leshchinskaia NP
    Vopr Virusol; 1986; 31(5):517-27. PubMed ID: 3541385
    [No Abstract]   [Full Text] [Related]  

  • 8. Live viral vaccines for respiratory and enteric tract diseases.
    Chanock RM; Murphy BR; Collins PL; Coelingh KV; Olmsted RA; Snyder MH; Spriggs MK; Prince GA; Moss B; Flores J
    Vaccine; 1988 Apr; 6(2):129-33. PubMed ID: 2838984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prospects of respiratory syncytial virus vaccines].
    Tarro G
    Ann Sclavo; 1980; 22(1):40-1. PubMed ID: 7247482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Respiratory syncytial virus and immune response: from the diagnosis of infection to prospects of vaccination].
    Pothier P
    Pediatrie; 1991; 46(8-9 Suppl):1-4. PubMed ID: 1665219
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunogen-induced enhanced pulmonary histopathology in the RSV cotton rat model.
    Hildreth SW; Baggs RR; Brownstein DG; Castleman WL; Paradiso PR
    Vaccine; 1993; 11(6):689-90. PubMed ID: 8322496
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection.
    Trudel M; Stott EJ; Taylor G; Oth D; Mercier G; Nadon F; Séguin C; Simard C; Lacroix M
    Arch Virol; 1991; 117(1-2):59-71. PubMed ID: 1706591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3-6 months after immunization.
    Hildreth SW; Baggs RR; Brownstein DG; Castleman WL; Paradiso PR
    Vaccine; 1993; 11(6):615-8. PubMed ID: 8322482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses.
    Murphy BR; Prince GA; Collins PL; Van Wyke Coelingh K; Olmsted RA; Spriggs MK; Parrott RH; Kim HW; Brandt CD; Chanock RM
    Virus Res; 1988 Aug; 11(1):1-15. PubMed ID: 2845680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.
    Murphy BR; Sotnikov AV; Lawrence LA; Banks SM; Prince GA
    Vaccine; 1990 Oct; 8(5):497-502. PubMed ID: 2251875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cells in respiratory syncytial virus (RSV) infection.
    Askonas BA; Openshaw P; Cannon M
    Adv Exp Med Biol; 1989; 257():9-17. PubMed ID: 2533461
    [No Abstract]   [Full Text] [Related]  

  • 18. [The immunization of adults against respiratory syncytial virus infection].
    Leshchinskaia NP; Korchanova NL; Pokrovskaia EE; Efremov BV; Padalko IuV
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Oct; (10):49-53. PubMed ID: 2609811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge.
    Stott EJ; Ball LA; Young KK; Furze J; Wertz GW
    J Virol; 1986 Nov; 60(2):607-13. PubMed ID: 3773052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory syncytial virus: reverse genetics and vaccine strategies.
    Collins PL; Murphy BR
    Virology; 2002 May; 296(2):204-11. PubMed ID: 12069519
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.